Literature DB >> 12082632

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.

Celina G Kleer1, Yanhong Zhang, Quintin Pan, Kenneth L van Golen, Zhi-Fen Wu, D Livant, Sofia D Merajver.   

Abstract

Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with a 5-year disease-free survival of less than 45%. Little is known about the genetic alterations that result in IBC. In our previous work, we found that WISP3 was specifically lost in human IBC tumors when compared to stage-matched, non-IBC tumors. We hypothesize that WISP3 has tumor suppressor function in the breast and that it may be a key genetic alteration that contributes to the unique IBC phenotype. The full-length WISP3 cDNA was sequenced and cloned into an expression vector. The resulting construct was introduced in to the SUM149 cell line that was derived from a patient with IBC and lacks WISP3 expression. In soft agar, stable WISP3 transfectants formed significantly fewer colonies than the controls. Stable WISP3 transfectants lost their ability to invade and had reduced angiogenic potential. WISP3 transfection was effective in suppressing in vivo tumor growth in nude mice. Mice bearing WISP3 expressing tumors had a significantly longer survival than those with vector-control transfectant tumors. Our data demonstrate that WISP3 acts as a tumor suppressor gene in the breast. Loss of WISP3 expression contributes to the phenotype of IBC by regulating tumor cell growth, invasion and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082632     DOI: 10.1038/sj.onc.1205462

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  59 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 2.  Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  Nat Rev Drug Discov       Date:  2011-12-01       Impact factor: 84.694

Review 3.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 4.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

5.  Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast.

Authors:  Michael J Hayes; Dafydd Thomas; Agnieszka Emmons; Thomas J Giordano; Celina G Kleer
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 6.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis.

Authors:  Tsu-Yao Cheng; Ming-Shiang Wu; Kuo-Tai Hua; Min-Liang Kuo; Ming-Tsan Lin
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  Dual roles of CCN proteins in breast cancer progression.

Authors:  Celina G Kleer
Journal:  J Cell Commun Signal       Date:  2016-08-12       Impact factor: 5.782

8.  CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor.

Authors:  Anupama Pal; Wei Huang; Kathy A Toy; Celina G Kleer
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

9.  The CCN family member Wisp3, mutant in progressive pseudorheumatoid dysplasia, modulates BMP and Wnt signaling.

Authors:  Yukio Nakamura; Gilbert Weidinger; Jennifer O Liang; Allisan Aquilina-Beck; Keiko Tamai; Randall T Moon; Matthew L Warman
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

10.  Comparative expression pathway analysis of human and canine mammary tumors.

Authors:  Paolo Uva; Luigi Aurisicchio; James Watters; Andrey Loboda; Amit Kulkarni; John Castle; Fabio Palombo; Valentina Viti; Giuseppe Mesiti; Valentina Zappulli; Laura Marconato; Francesca Abramo; Gennaro Ciliberto; Armin Lahm; Nicola La Monica; Emanuele de Rinaldis
Journal:  BMC Genomics       Date:  2009-03-27       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.